Checkmate 9la clinical study10/10/2023 ![]() Stenehjem: Advisory/Consultancy: Bristol-Myers Squibb. Fundingīristol-Myers Squibb, Princeton, NJ, USA. Legal entity responsible for the studyīristol-Myers Squibb, Princeton, NJ, USA. ![]() Writing and editorial assistance was provided by Analysis Group, Inc., and funded by Bristol-Myers Squibb. N+I+C was associated with lower ACAE costs compared to C, P+C, and A+C. AEs with ≥10% any-grade or ≥2% grade 3/4 incidence included.3. AEs with ≥15% any-grade incidence included.2. Costs were higher when a lower incidence threshold was applied Table: 1316PĬost of grade 3/4 ACAEs for N+I+C vs P+C and A+Cġ. Rates of hematological AEs were lower for N+I+C than comparators. Compared to P+C and A+C, N+I+C had lower costs (Table). Within CM-9LA, the mean ACAE cost per patient for N+I+C vs. Differences across trials were assessed both overall and adjusted for duration of treatment (DOT). Non-squamous (NSQ) patients in CM-9LA were compared to KN-189 and IM130 squamous (SQ) patients were compared to KN-407. Costs of C in each trial were also estimated. P+C and A+C, the threshold used in the comparator trial was applied to CM-9LA. C within CM-9LA, grade 3/4 events for ACAEs meeting a ≥15% all-grade incidence threshold were included. Costs were obtained from the US Healthcare Cost and Utilization Project. Grade 3/4 ACAE rates were obtained from individual patient data from the CheckMate (CM)-9LA clinical trial and aggregate data from the KEYNOTE (KN)-189, KN-407, and IMpower130 (IM130) trials. chemotherapy (C), pembrolizumab + chemotherapy (P+C), and atezolizumab + chemotherapy (A+C) as first-line therapy for Stage IV or recurrent non-small-cell lung cancer. This study compared all-cause adverse event (ACAE) cost per patient of nivolumab + ipilimumab + limited chemotherapy (N+I+C) vs.
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |